Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin alone or with tucatinib in HER2-low or HER2-positive solid tumors
2023-507555-29-00Phase 2Authorised
- Sponsor
- Seagen Inc.
- Start
- Jun 2024
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, open-label trial of disitamab vedotin and tucatinib in breast cancer, gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Seagen Inc. Primary endpoints: Incidence of dose-limiting toxicities, Adverse events and 3 more. Planned start Jun 2024; status: authorised.
02
Drugs
disitamab vedotintucatinib
03
Conditions
breast cancergastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2023-507555-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507555-29-00.